Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Biohit Oyj (BIOBV.HE)
Helsinki, FI
Helsinki-based Biohit Oyj is a biotechnology company that specializes in developing and distributing diagnostic tests and analytical systems worldwide for healthcare providers and research institutions. Their comprehensive portfolio of diagnostic solutions includes the GastroPanel test, designed for evaluating stomach conditions and associated risks, alongside tests for active vitamin B12 levels (Biohit Active B12) and vitamin D status (Biohit Total). They also offer the Biohit Calprotectin test, various methods for detecting Helicobacter pylori infection from biopsy samples, the ColonView Quick Test for identifying fecal occult blood, rapid tests for Lactose Intolerance and Celiac Disease, and the GA-map Dysbiosis test for detailed gut microbiota DNA analysis. Beyond diagnostics, Biohit manufactures products that bind carcinogenic acetaldehyde into harmless compounds, such as Acetium capsules for individuals with low stomach acidity, and Acetium lozenges, which neutralize acetaldehyde in smokers' saliva. The company also supplies monoclonal antibodies crucial for research in cellular pathology, neurobiology, oncology, and human gastric biomarkers. Additionally, their offerings extend to laboratory instrumentation, including microplate readers, strip washers, quick test readers, and the ThunderBolt automated immunoassay analyzer, complemented by comprehensive service laboratory provisions. Biohit Oyj was founded in 1988.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.95% | +11.44% | +3.54% | +6.05% | -23.10% | -26.94% | -5.73% | +52.02% | +25.24% | -50.56% | -40.23% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+9.8% ★ Q4'25: +25.8% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+5.9% Q4'25: +262.5% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-10.2% Q4'25: +2.4% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%+20.4% ★ Q4'25: +21.7% (vs Q4'23)
-
ROIC Biotechnology: -16.1%+25.5% ★ Q4'25: +61.6% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%-0.1% ★ Q4'25: +0.6% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.43× ★ Q4'25: 0.18× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
6.05M
est: 71.00M (-91.5%)
|
10.95M
est: 71.00M (-84.6%)
|
13.08M
est: 12.40M (+5.5%)
|
14.30M
est: 14.30M (+0.0%)
|
15.70M
est: 15.70M (+0.0%)
|
16.96M
16.96M – 16.96M
+8.0% YoY
|
18.67M
18.67M – 18.67M
+10.1% YoY
|
21.21M
21.21M – 21.21M
+13.6% YoY
|
24.61M
24.61M – 24.61M
+16.0% YoY
|
| EBITDA |
-2.58M
est: 7.04M (-136.7%)
|
1.61M
est: 7.04M (-77.2%)
|
2.69M
est: 1.23M (+118.6%)
|
3.50M
est: 5.81M (-39.7%)
|
3.70M
est: 6.38M (-42.0%)
|
6.89M
6.89M – 6.89M
+8.0% YoY
|
7.59M
7.59M – 7.59M
+10.1% YoY
|
8.62M
8.62M – 8.62M
+13.6% YoY
|
10.00M
10.00M – 10.00M
+16.0% YoY
|
| EBIT |
-2.64M
est: -1.27M (-107.6%)
|
1.13M
est: -1.27M (+188.9%)
|
2.33M
est: -221.7K (+1,149.1%)
|
3.20M
est: 6.89M (-53.6%)
|
3.20M
est: 7.57M (-57.7%)
|
8.17M
8.17M – 8.17M
+8.0% YoY
|
9.00M
9.00M – 9.00M
+10.1% YoY
|
10.23M
10.23M – 10.23M
+13.6% YoY
|
11.86M
11.86M – 11.86M
+16.0% YoY
|
| Net Income |
-2.92M
|
601.0K
|
1.85M
est: 1.67M (+10.6%)
|
2.60M
est: 2.28M (+14.1%)
|
2.70M
est: 2.70M (0.0%)
|
2.22M
2.22M – 2.22M
-17.9% YoY
|
2.55M
2.55M – 2.55M
+15.1% YoY
|
2.79M
2.79M – 2.79M
+9.5% YoY
|
3.51M
3.51M – 3.51M
+25.5% YoY
|
| SGA |
1.62M
est: 18.87M (-91.4%)
|
1.46M
est: 18.87M (-92.3%)
|
4.09M
est: 3.29M (+24.0%)
|
6.70M
est: 3.68M (+82.2%)
|
2.90M
est: 4.04M (-28.2%)
|
4.36M
4.36M – 4.36M
+8.0% YoY
|
4.80M
4.80M – 4.80M
+10.1% YoY
|
5.46M
5.46M – 5.46M
+13.6% YoY
|
6.33M
6.33M – 6.33M
+16.0% YoY
|
| EPS |
-0.20
|
0.04
|
0.12
est: 0.11 (+9.1%)
|
0.17
est: 0.15 (+13.3%)
|
0.18
est: 0.18 (+1.3%)
|
0.15
0.15 – 0.15
-17.9% YoY
|
0.17
0.17 – 0.17
+15.1% YoY
|
0.18
0.18 – 0.18
+9.5% YoY
|
0.23
0.23 – 0.23
+25.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-28 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-27 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-26 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-25 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-22 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-21 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-20 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-19 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-18 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-15 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-13 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-12 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-11 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-08 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-07 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-06 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-05 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-04 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-30 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-29 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-28 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-27 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-24 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-23 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-22 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-21 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-20 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-17 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-16 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Graham Johnson | Managing Director of Biohit Healthcare Ltd - UK | — | — |
| Jussi Hahtela | President & Chief Executive Officer | — | male |
| Jussi Sorvo | Chief Financial Officer | — | male |
| Kati Piironen | Chief Technology Officer | — | female |
| Osmo Antero Suovaniemi | Founder, Deputy Chief Executive Officer, Member of Scientific Advisory Board & Director | — | — |
| Ville Suovaniemi | Head of Global Sales & Marketing | — | male |
| Yulia Kubacheva | Head of Diagnostics Department - Biohit Russia | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BIOBV.HE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
